Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease

CER2934
2007 Vol.25, N°1
PI 0023, PF 0028
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 17417986 [PubMed]

Abstract

OBJECTIVES:
To study the potential effectiveness of tumor necrosis factor a (TNF-α) inhibitor treatment for pulmonary fibrosis associated with a collagen vascular disease, CVD (rheumatoid arthritis, RA and systemic sclerosis, SSc) refractory to conventional treatment.
METHODS:
Four patients (three men with RA, one woman with SSc) were treated with infliximab. All patients received 3mg/kgr of infliximab at intervals 0, 2 and 6 weeks, and then maintenance infusions every 8 weeks afterwards for at least a 12-month period. Patients had active disease despite treatment with corticosteroids and other immunomodulatory agents.
RESULTS:
Treatment was well-tolerated from all patients. Pulmonary fibrosis remained stable during treatment in terms of symptoms, pulmonary function tests (PFTs) and High resolution computed tomography (HRCT) appearance. As expected, a clinical response was observed in joint symptoms in patients with RA as evaluated by the DAS28 (Disease Activity Score, the 28 joint version).
CONCLUSIONS:
This study suggests that inhibition of TNF-α with infliximab may stabilize the progression of pulmonary fibrosis associated with CVD. Prospective, controlled trials are necessary to determine the efficacy of infliximab in pulmonary fibrosis associated CVD.